Indeed, the situation of BL patients and the c-MYC-altered subset of DLBCL patients harboring DDX3X LOF mutations may render the use of DDX3 inhibitors beneficial for this selected group of patients. Here, DDX3X is linked to diffuse large B-cell lymphoma.